Bradycor

Bradycor

A proprietary bradykinin antagonist, which made it to Phase II clinical trials for treating inflammation—e.g., for systemic inflammatory response syndrome (SIRS)—and Four Corners hantavirus infections. The drug sponsor ended trials in the mid-1990s.
References in periodicals archive ?
Nonetheless, we are examining the question closely and have elected to stop enrollment in our other Bradycor trials until we have completed our analysis.
The objective of this study, currently designed to enroll up to 160 patients in about 15 North American sites, is to investigate the efficacy of Bradycor in reducing the edema, or swelling, of brain tissue and improving patient outcome following head injuries.
Its lead bradykinin antagonist, Bradycor, is currently in separate Phase 2 trials for sepsis and multiple trauma, and design is underway for a multicenter trial for head trauma patients.
In that trial, 504 patients with systemic inflammatory response syndrome (SIRS) and presumed sepsis received placebo or one of three doses of Bradycor via a three-day intravenous infusion.
CDC), a research funding corporation that has provided partial financing for the development of Bradycor.
Of the 112 patients, 84 received Bradycor and 28 placebo.
The 20-patient, single-blind, placebo-controlled study demonstrated that patients who received Bradycor for seven days showed a statistically significant, 68 percent relative reduction in peak intracranial pressure (ICP) as compared to those on placebo, according to Timothy C.
Jerde noted that subsequent to the second quarter the company reported that data from its first Phase II trial with Bradycor in systemic inflammatory response syndrome (SIRS) and presumed sepsis was not clinically or statistically significant.
Anatibant is one thousand times more potent than Bradycor, the compound used in that previous study, and has a much better pharmacodynamic profile," said Rowland Furcha, project manager for Xytis.
The Bradycor trial was stopped early for reasons unrelated to efficacy, but there were positive trends in mortality and performance.
Marmarou reported that Bradycor showed positive trends in functional outcome as measured by the Glasgow Outcome Score at 3 and 6 months.
Providing for the continued development of Bradycor has been a high priority for us.